In this issue:
Ultra-processed food intake and cancer risk
Immune-related AEs with PD1 and PDL1 inhibitors
Adjuvant chemotherapy: 3 vs 6 months in stage III colon cancer
Osimertinib in EGFR mutation-positive NSCLC
Nivolumab + ipilimumab in dMMR mCRC
Mortality after surgery vs SBRT for early-stage NSCLC
Improved survival after PTR in mCRC
Trifluridine/tipiracil effective across mCRC subgroups
Trifluridine/tipiracil monotherapy in Asian patients with previously treated mCRC
No benefits for bevacizumab maintenance in mCRC
Please login below to download this issue (PDF)